All In Biotech

NDA 018132 · Hospira

Dopamine Hydrochloride

Dopamine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Sep 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

May 19, 1981

Approved uses

1

Original approval plus efficacy supplements

Registered trials

586

103 Phase 3, 70 recruiting

FAERS reports

725

694 serious, 313 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 19, 1981 Original approval
4 products under this application
  • DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 80MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 80MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 160MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DOPAMINE HYDROCHLORIDE · DOPAMINE HYDROCHLORIDE 40MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dopamine" as an intervention, any sponsor and status, largest first.

All 586 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective47
  • hypotension46
  • platelet count decreased46
  • pneumonia46
  • pyrexia41
  • renal impairment41
  • sepsis37
  • blood pressure decreased35
  • cardiac failure35
  • condition aggravated35
  • renal failure34
  • anaemia33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200454
20059
200612
200722
200838
200932
201042
201145
201239
201338
201418
201528
201631
201725
201825
201934
202025
202148
202245
202331
202437
202530
202614

Recalls

1 FDA enforcement reports for this application.

  • Sep 4, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01). Other

  • Current · updated Nov 9, 2026

    Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,850 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.